Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"
Jump to navigation
Jump to search
Template documentation
(Remove now unnecessary 1px width hack from table footer cell) |
(→Documentation: Move notes to top (above references)) |
||
| Line 36: | Line 36: | ||
{{Improve documentation|date=March 2019}} | {{Improve documentation|date=March 2019}} | ||
==Notes and references== | ==Notes and references== | ||
| − | |||
{{Notelist}} | {{Notelist}} | ||
{{Notefoot}} | {{Notefoot}} | ||
| + | {{Reflist}} | ||
}} | }} | ||
[[Category:Medication templates]] | [[Category:Medication templates]] | ||
[[Category:Templates that generate named references]] | [[Category:Templates that generate named references]] | ||
</noinclude> | </noinclude> | ||
Revision as of 11:40, 27 March 2019
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) | Placebo (n = 8102) |
CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events ( non-fatal myocardial infarction, death) |
1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) |
30 23 6 |
37 30 7 | ||||||
| Invasive breast cancer[lower-alpha 1] | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Index[lower-alpha 2] | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosis[lower-alpha 3] | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fractures[lower-alpha 3] | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fractures[lower-alpha 3] | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| Sources: [1][2] | |||||||||
| This template's documentation is missing, inadequate, or does not accurately describe its functionality and/or the parameters in its code. Please help to expand and improve it. (March 2019) |
Notes and references
- ↑ Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
- ↑ A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
- ↑ 3.0 3.1 3.2 Not included in Global Index.
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |
Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing